Tango Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Tango Therapeutics reported positive Phase 1/2 data for vopimetostat plus Revolution Medicines' daraxonrasib in MTAP-deleted, RAS-mutant pancreatic cancer, achieving 92% objective response rate and 90% six-month progression-free survival. The company holds $1.0 billion in cash as of June 30, 2026, and appointed Fatma Ocak as Chief Commercialization Officer (effective Aug 17, 2026) and Robert Azelby as Board Chairman (Aug 6, 2026). H1 2026 net loss was $100.9 million ($0.68/share) on R&D spend of $70.7 million.
Why this rating
92% response rate in Phase 1/2 validates lead asset; moves company toward Phase 3 pivotal trial. $1B cash (190% of market cap) funds development, mitigating financing risk. Senior oncology hires strengthen commercialization readiness, but clinical-stage biotech remains binary-outcome dependent.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.